局部晚期乳腺癌分子病理分型与新辅助化疗疗效的相关性及预后因素分析

摘要

Objective To analyze the relevance between molecular pathological type and neoadjuvant chemotherapy in locally advanced breast cancer as well as its prognostic factors. Method Clinicopathological features of neoadju-vant chemotherapy in locally advanced breast cancer patients were retrospective analyzed from July 1998 to April 2012. Result 653 cases were divided into HR+/ HER2-,HR+/HER2+,HR-/HER2+and HR-/HER2-types with primary tumor's pathological complete remission rate of 11. 07%,18. 84%,38. 21% and 34. 15% as well as axilla-ry lymph node pathologic complete remission rate 26. 05%,28. 99%,40. 65% and 57. 14%. Multivariate analysis indicates that pathological response rate and the number of metastatic lymph nodes are the main prognostic factors. Conclusion Molecular pathological type are closely related to the effect of neoadjuvant chemotherapy, meanwhile, pathological response of primary tumor and the number of metastatic lymph nodes are the main prognostic factors.%目的探讨局部晚期乳腺癌新辅助化疗疗效与分子病理分型的相关性及影响预后的因素。方法回顾性分析653例接受新辅助化疗的乳腺癌患者的临床病理资料。结果患者根据免疫组化结果分为HR+/HER2-型、HR+/HER2+型、HR-/HER2+型、HR-/HER2-型，肿瘤病理完全缓解率分别为11.07%、18.84%、38.21%和34.15%，腋窝淋巴结病理完全缓解率为26.05%、28.99%、40.65%、57.14%。多因素分析提示肿瘤病理缓解率和转移淋巴结数目是影响预后的主要因素。结论分子病理分型与新辅助化疗效果密切相关，新辅助化疗后原发肿瘤的病理反应和转移淋巴结数目是影响预后的主要因素。